PKM and lip and oral cavity carcinoma: Wu et al. reveals that inhibiting PKM2 nuclear translocation in CAFs through TGF-βRII overexpression crucially disrupts glycolytic activation, uncovering the critical function of PKM2 localization in CAFs-mediated metabolic reprogramming and suggesting a therapeutic target for oral cancer [41].